Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study
2013 (English)In: Leukemia research: a Forum for Studies on Leukemia and Normal Hemopoiesis, ISSN 0145-2126, E-ISSN 1873-5835, Vol. 37, no 2, 162-168 p.Article in journal (Refereed) Published
EXELS is an ongoing phase IV non-interventional study; 3643 high-risk patients with essential thrombocythemia (ET) were recruited across 13 European countries. We report patient characteristics and cytoreductive treatment patterns of ET across Europe. Hydroxycarbamide (HC; 64.3%) and anagrelide (22.0%) were the two main cytoreductive treatments prescribed. The proportions of patients taking either HC or anagrelide varied across countries, as did the number of patients receiving anti-aggregatory therapy in addition to cytoreductive treatment. This real-world evidence demonstrates that, generally, treatment patterns of ET across Europe adhere to expert recommendations, with some notable variations between countries.
Place, publisher, year, edition, pages
2013. Vol. 37, no 2, 162-168 p.
Essential thrombocythemia, Cytoreductive treatment, Anagrelide, Hydroxycarbamide, Interferon
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-194739DOI: 10.1016/j.leukres.2012.11.004ISI: 000313636700008OAI: oai:DiVA.org:uu-194739DiVA: diva2:606506